HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takaichi Shimozato Selected Research

Arthritis (Polyarthritis)

5/2012Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.
8/2010Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: part 3.
10/2007Anti-type II collagen antibody accelerates arthritis via CXCR2-expressing cells in IL-1 receptor antagonist-deficient mice.
10/2006Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis.
1/2005R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models.
4/2003Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis.
8/2002The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takaichi Shimozato Research Topics

Disease

7Arthritis (Polyarthritis)
05/2012 - 08/2002
3Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
12/2016 - 05/2011
3Rheumatoid Arthritis
08/2010 - 04/2003
2Experimental Arthritis
08/2010 - 01/2005
1Inflammation (Inflammations)
01/2017
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2017
1Lymphopenia (Lymphocytopenia)
01/2016
1Bradycardia
08/2014
1Animal Disease Models
05/2012
1Multiple Sclerosis
05/2011
1Pain (Aches)
08/2010
1Sepsis (Septicemia)
05/2006
1Hyperalgesia
01/2005

Drug/Important Bio-Agent (IBA)

4Collagen Type II (Type II Collagen)IBA
10/2007 - 08/2002
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2010 - 08/2002
2AntibodiesIBA
01/2017 - 10/2006
2CS 0777IBA
12/2016 - 05/2011
2Chemotactic FactorsIBA
10/2007 - 10/2006
2CytokinesIBA
04/2003 - 08/2002
1Interleukin-17 ReceptorsIBA
01/2017
1Interleukin-17 (Interleukin 17)IBA
01/2017
1LyasesIBA
01/2016
1sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
01/2016
1caramel coloring (ammonia caramel)IBA
01/2016
1CS-2100IBA
05/2012
1Therapeutic UsesIBA
08/2010
1CollagenIBA
08/2010
1Analgesics (Analgesic Drugs)IBA
08/2010
1Mitogen-Activated Protein Kinase 13IBA
08/2010
1Phosphotransferases (Kinase)IBA
08/2010
1Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
10/2007
1Anaphylatoxin C5a ReceptorIBA
10/2006
1LipopolysaccharidesIBA
10/2006
1Gi-Go GTP-Binding Protein alpha Subunits (Gi alpha Subunit)IBA
10/2006
1Pertussis ToxinIBA
10/2006
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
10/2006
1Glucose (Dextrose)FDA LinkGeneric
05/2006
1E5564IBA
05/2006
1Pharmaceutical PreparationsIBA
05/2006
1Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
01/2005
1p38 Mitogen-Activated Protein KinasesIBA
01/2005
1Methotrexate (Mexate)FDA LinkGeneric
01/2005
1Celecoxib (Celebrex)FDA Link
01/2005
12- (4- fluorophenyl)- 4- (1- phenethyl- 1,2,3,6- tetrahydropyridin- 4- yl)- 3- (pyridin- 4- yl)- 1H- pyrroleIBA
01/2005
1Immunoglobulin G (IgG)IBA
04/2003
1IgG Receptors (Fc gamma RI)IBA
04/2003
1AutoantibodiesIBA
04/2003
1Monoclonal AntibodiesIBA
08/2002
1Interleukin-1beta (Interleukin 1 beta)IBA
08/2002
1Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)IBA
08/2002
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
08/2002
1ChemokinesIBA
08/2002
1Recombinant ProteinsIBA
08/2002
1Interleukin-6 (Interleukin 6)IBA
08/2002

Therapy/Procedure

3Oral Administration
01/2017 - 08/2014